See the DrugPatentWatch profile for Onivyde
What is Onivyde?
Onivyde (nal-IRI) is an encapsulated irinotecan product used for the treatment of pancreatic cancer. It is a liposomal formulation of irinotecan hydrochloride, designed to improve drug delivery and potentially reduce toxicity compared to conventional irinotecan. The liposomes encapsulate the irinotecan, releasing it slowly over time [1].
How does Onivyde work?
Onivyde works by inhibiting topoisomerase I, an enzyme crucial for DNA replication and repair in cancer cells. By blocking this enzyme, irinotecan causes DNA breaks, leading to cancer cell death. The liposomal delivery system of Onivyde aims to enhance the concentration of irinotecan at the tumor site while minimizing exposure to healthy tissues [1].
How is Onivyde administered?
Onivyde is administered intravenously. It is typically given in combination with other chemotherapy agents, such as fluorouracil and leucovorin, as part of a treatment regimen for metastatic pancreatic adenocarcinoma [1].
When does Onivyde's patent expire?
Information regarding specific patent expiry dates for Onivyde is available through specialized databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, including expiry dates and any associated exclusivity periods [2].
Can biosimilars of Onivyde be developed?
The development of biosimilars for Onivyde, like other complex biologic or encapsulated drugs, involves demonstrating high similarity to the reference product. Regulatory pathways for biosimilars are established, but the complexity of liposomal formulations may present unique challenges in demonstrating equivalence compared to simpler small-molecule drugs [3].
What are the risks and side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, stomatitis, and abdominal pain. More serious side effects can occur, such as severe diarrhea, neutropenia, and hypersensitivity reactions. Patients are closely monitored for these potential adverse events during treatment [1].
What are the treatment outcomes for Onivyde?
Clinical trials have shown that Onivyde, in combination with fluorouracil and leucovorin, can improve overall survival and progression-free survival in patients with metastatic pancreatic adenocarcinoma compared to fluorouracil and leucovorin alone. These outcomes are evaluated based on data from controlled studies [1].
How does Onivyde compare to other pancreatic cancer treatments?
Onivyde offers an alternative treatment option for patients with metastatic pancreatic cancer, particularly those whose disease has progressed after initial chemotherapy. Its liposomal formulation aims to improve the therapeutic index of irinotecan. Other treatments for pancreatic cancer include various chemotherapy regimens, targeted therapies, and immunotherapy, depending on the specific characteristics of the cancer and the patient [4].
What is the pricing of Onivyde?
The cost of Onivyde can vary significantly based on factors such as dosage, insurance coverage, and geographic location. Patients and healthcare providers often consult with pharmaceutical manufacturers or specialized patient assistance programs to navigate treatment costs [5].
Sources:
[1] https://www.onivyde.com/
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/vaccines-blood-biologics/biosimilars/what-biosimilar-and-interchangeable-biosimilar
[4] https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq
[5] https://www.goodrx.com/onivyde